Crossing the next frontier to give you a fair chance to fight
Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation therapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms to enhance patient's responsiveness to treatments in indications where dysregulated immunity hampers efficacy, including inflammatory bowel diseases, solid tumor cancers and some infectious diseases.
EXL01 - Exeliom's lead drug candidate - is a first-in-class oral drug with a novel mechanism of action that demonstrates enhanced activation of key regulators of the innate immune system.
In immuno-inflammation, EXL01 facilitates resolution of inflammation in a non-suppressive manner by favoring a regulatory phenotype of antigen presenting cells, downregulating proinflammatory T cells and upregulating a specific Treg subpopulation.
In immuno-oncology, immune checkpoint inhibitors binding to their targets shift the intracellular signalling induced by EXL01 with upregulation of Th1 immunity and synergistic anti-tumour effects.
EXL01 harnesses the immuno-modulatory properties of the commensal bacterium Faecalibacterium prausnitzii.
... in conditions where dysregulated immunity hampers efficacy of existing treatments
EXL01 is being evaluated in several clinical trials, including a phase I trial in Crohn's disease, two phase II trials in immuno-oncology in combination with immune checkpoint inhibitors (Gastric cancer and Non-small cell lung cancer), and one phase I/II trial in the prevention of recurrent C. difficile infection. Two additional Phase II studies evaluated EXL01 are planned to start in end of 2024: one in hepatocellular carcinoma in combination with an immune checkpoint inhibitor and one in postoperative Crohn's disease.
Overall, more than 300 patients across 6 indications will receive EXL01, generating an extensive dataset to demonstrate its therapeutic and commercial potential.
Giving patients a fair chance to fight is why we seek out unexplored therapeutic
solutions, and why we founded Exeliom Biosciences.
Exeliom is based on strong scientific foundations and has a world-renowned team, led by Pr. Harry Sokol, gastroenterologist and hepatologist at Saint-Antoine Hospital,AP-HP and Sorbonne University, Dr. Philippe Langella, research director at INRAE, and Pr. Patrick Gervais, process engineering specialist at AgroSup.
Founded in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.
The company has been awarded the ‘Deeptech’ and ‘I-Lab’ awards by Bpifrance, and the ‘EIC Accelerator’ by the European Innovation Council Fund. It has also received financial supportfrom the Crohn's & Colitis Foundation of America.
Giving patients a fair chance to fight is why we seek out unexplored therapeutic solutions, and why we founded Exeliom Biosciences.
